Altman Advisors Inc. Purchases 91 Shares of Zoetis Inc. (NYSE:ZTS)

Altman Advisors Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 1.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,284 shares of the company’s stock after buying an additional 91 shares during the period. Altman Advisors Inc.’s holdings in Zoetis were worth $1,635,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Forum Financial Management LP increased its stake in Zoetis by 0.8% in the fourth quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock valued at $1,458,000 after purchasing an additional 56 shares in the last quarter. Prossimo Advisors LLC increased its position in shares of Zoetis by 1.7% during the fourth quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after acquiring an additional 57 shares in the last quarter. River Street Advisors LLC increased its position in shares of Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after acquiring an additional 58 shares in the last quarter. Perigon Wealth Management LLC increased its position in shares of Zoetis by 0.3% during the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock worth $4,654,000 after acquiring an additional 59 shares in the last quarter. Finally, Revolve Wealth Partners LLC increased its position in shares of Zoetis by 5.0% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,281 shares of the company’s stock worth $253,000 after acquiring an additional 61 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZTS. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Stifel Nicolaus decreased their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Piper Sandler reissued an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. HSBC cut their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Finally, Barclays cut their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $211.75.

Get Our Latest Research Report on Zoetis

Zoetis Stock Performance

ZTS traded up $4.41 during midday trading on Wednesday, reaching $173.28. The company had a trading volume of 2,583,290 shares, compared to its average volume of 3,142,086. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The stock has a market cap of $79.07 billion, a PE ratio of 33.55, a P/E/G ratio of 2.60 and a beta of 0.86. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The business has a 50-day moving average price of $165.18 and a two-hundred day moving average price of $179.12.

Zoetis (NYSE:ZTSGet Free Report) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.31 earnings per share. On average, sell-side analysts expect that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the sale, the executive vice president now directly owns 15,723 shares in the company, valued at approximately $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.